Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

BACKGROUND: Adoptive transfer of T cells genetically engineered with a chimeric antigen receptor (CAR) has successfully been used to treat both chronic and acute lymphocytic leukemia as well as other hematological cancers. Experimental therapy with CAR-engineered T cells has also shown promising res...

Descripción completa

Detalles Bibliográficos
Autores principales: Hillerdal, Victoria, Ramachandran, Mohanraj, Leja, Justyna, Essand, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899402/
https://www.ncbi.nlm.nih.gov/pubmed/24438073
http://dx.doi.org/10.1186/1471-2407-14-30

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899402/
https://www.ncbi.nlm.nih.gov/pubmed/24438073
http://dx.doi.org/10.1186/1471-2407-14-30

Ejemplares similares